344 related articles for article (PubMed ID: 7503805)
1. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
2. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
3. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes.
Li Y; Li NY; Sellers EM
Eur J Drug Metab Pharmacokinet; 1997; 22(4):295-304. PubMed ID: 9512924
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.
Prueksaritanont T; Gorham LM; Hochman JH; Tran LO; Vyas KP
Drug Metab Dispos; 1996 Jun; 24(6):634-42. PubMed ID: 8781778
[TBL] [Abstract][Full Text] [Related]
6. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
[TBL] [Abstract][Full Text] [Related]
7. Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes.
Takemoto K; Yamazaki H; Tanaka Y; Nakajima M; Yokoi T
Xenobiotica; 2003 Jan; 33(1):43-55. PubMed ID: 12519693
[TBL] [Abstract][Full Text] [Related]
8. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
9. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
Halliday RC; Jones BC; Smith DA; Kitteringham NR; Park BK
Br J Clin Pharmacol; 1995 Oct; 40(4):369-78. PubMed ID: 8554939
[TBL] [Abstract][Full Text] [Related]
10. Catalytic specificity of CYP2D isoforms in rat and human.
Hiroi T; Chow T; Imaoka S; Funae Y
Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
[TBL] [Abstract][Full Text] [Related]
11. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
Zanger UM; Vilbois F; Hardwick JP; Meyer UA
Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
[TBL] [Abstract][Full Text] [Related]
12. Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver.
Hichiya H; Takemi C; Tsuzuki D; Yamamoto S; Asaoka K; Suzuki S; Satoh T; Shinoda S; Kataoka H; Narimatsu S
Biochem Pharmacol; 2002 Oct; 64(7):1101-10. PubMed ID: 12234613
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Jacqz-Aigrain E; Gueguen M; Zanger UM; Robieux I; Alvarez F
Biochem Pharmacol; 1991 Jun; 41(11):1657-63. PubMed ID: 2043154
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
Boobis AR; Murray S; Hampden CE; Davies DS
Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
[TBL] [Abstract][Full Text] [Related]
15. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.
Hashizume T; Imaoka S; Mise M; Terauchi Y; Fujii T; Miyazaki H; Kamataki T; Funae Y
J Pharmacol Exp Ther; 2002 Jan; 300(1):298-304. PubMed ID: 11752129
[TBL] [Abstract][Full Text] [Related]
16. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation.
Narimatsu S; Masubuchi Y; Hosokawa S; Ohmori S; Kitada M; Suzuki T
Biol Pharm Bull; 1994 Jun; 17(6):803-7. PubMed ID: 7951142
[TBL] [Abstract][Full Text] [Related]
17. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.
Narimatsu S; Takemi C; Kuramoto S; Tsuzuki D; Hichiya H; Tamagake K; Yamamoto S
Chirality; 2003 May; 15(4):333-9. PubMed ID: 12666241
[TBL] [Abstract][Full Text] [Related]
18. Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver.
Chow T; Imaoka S; Hiroi T; Funae Y
Drug Metab Dispos; 1999 Feb; 27(2):188-92. PubMed ID: 9929501
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.
Masimirembwa CM; Hasler JA; Johansson I
Eur J Clin Pharmacol; 1995; 48(1):35-8. PubMed ID: 7621845
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.
Nakamura K; Yokoi T; Inoue K; Shimada N; Ohashi N; Kume T; Kamataki T
Pharmacogenetics; 1996 Oct; 6(5):449-57. PubMed ID: 8946477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
